Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data

作者: Henry WC Leung , Agnes LF Chan

DOI: 10.1517/14740338.2015.1089231

关键词:

摘要: Background: We conducted a meta-analysis to assess the overall risk of cardiac toxicity associated with trastuzumab treatment in elderly breast cancer patients. Methods: searched databases from PubMed, EMBASE and Cochrane Central Registry Controlled Trials identify relevant studies. Statistical analyses were calculate incidence rate, hazard ratio (HR) 95% CIs using fixed effects model. Results: A total 116,342 360 patients five cohort studies two randomized clinical trials (RCTs) included for analysis. The pooled incidences symptomatic congestive heart failure (CHF) CHF/HF/CM 6.4% (95% CI 4.1% – 9.4) 16.4% 16.19% 16.61) median age 67.5 years RCTs (60 75), 71 (66 80+), 74.5 (65 89), 75 81+) 79.5 99) studies, respectively. Trastuzumab was significantly correlated an increased defined tox...

参考文章(29)
E. Burandt, G. Sauter, HER2-ASCO-Guidelines Pathologe. ,vol. 31, pp. 285- 291 ,(2010) , 10.1007/S00292-010-1348-4
Gustavo A Viani, Sergio L Afonso, Eduardo J Stefano, Ligia I De Fendi, Francisco V Soares, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer. ,vol. 7, pp. 153- 153 ,(2007) , 10.1186/1471-2407-7-153
Ching-Hung Lin, Jau-Yu Liau, Yen-Shen Lu, Chiun-Sheng Huang, Wei-Chung Lee, Kuan-Ting Kuo, Ying-Chun Shen, Sung-Hsin Kuo, Chieh Lan, Jacqueline Ming Liu, Wun-Hon Kuo, King-Jen Chang, Ann-Lii Cheng, Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia Cancer Epidemiology, Biomarkers & Prevention. ,vol. 18, pp. 1807- 1814 ,(2009) , 10.1158/1055-9965.EPI-09-0096
Jing Zhao, Hong Liu, Meng Wang, Lin Gu, Xiaojing Guo, Feng Gu, Li Fu, Characteristics and prognosis for molecular breast cancer subtypes in Chinese women Journal of Surgical Oncology. ,vol. 100, pp. 89- 94 ,(2009) , 10.1002/JSO.21307
Luigi Tarantini, Giovanni Cioffi, Stefania Gori, Fausto Tuccia, Lidia Boccardi, Daniella Bovelli, Chiara Lestuzzi, Nicola Maurea, Stefano Oliva, Giulia Russo, Pompilio Faggiano, Italian Cardio-Oncologic Network, None, Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer Journal of Cardiac Failure. ,vol. 18, pp. 113- 119 ,(2012) , 10.1016/J.CARDFAIL.2011.10.015
Tao Chen, Tao Xu, Yang Li, Chun Liang, Juxiang Chen, Yicheng Lu, Zonggui Wu, Shenhong Wu, Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treatment Reviews. ,vol. 37, pp. 312- 320 ,(2011) , 10.1016/J.CTRV.2010.09.001
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial The Lancet. ,vol. 369, pp. 29- 36 ,(2007) , 10.1016/S0140-6736(07)60028-2